Chlordane: 24-month tumorigenicity and chronic toxicity test in mice.
Four groups of 80 ICR SPF mice of each sex were fed 0-12.5 ppm technical chlordane for 104 weeks. Male and female mice were examined for hematological, biochemical, urinary, and pathological changes at 52 and 104 weeks of exposure. Serum AST (= SGOT) and ALT (= SGPT) were elevated in treated males and females, liver weights were increased in the 12.5-ppm groups, and masses were seen in the livers of 12.5-ppm males. Increased liver cell volume was seen in 5- and 12.5-ppm males and females, while hepatocyte degeneration and necrosis were seen only in treated males. Hepatic hemangiomas and hepatocellular adenomas typically occurred together and were significantly increased in 12.5-ppm males. No other significant changes were detected. However, the incidence of tumors in the 12.5-ppm males was within the range of historical controls. Accordingly, there was no evidence that chlordane induced tumors in the ICR mice. A long-term no-observed-effect level (NOEL) of 1 ppm chlordane in the diet was found.
Khasawinah
A M
AM
Velsicol Chemical Corporation, Rosemont, Illinois 60018-5119.
Grutsch
J F
JF
D000818:Animals; D001774:Blood Chemical Analysis; D015197:Carcinogenicity Tests; D002706:Chlordan / Q000009:adverse effects / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D013047:Specific Pathogen-Free Organisms; D013997:Time Factors
D002706:Chlordan